Professor of Pediatrics and Medicine, Emeritus
Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J. 2001 Nov; 142(5):790-8.
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
Rajasekhar D, Kestin AS, Bednarek FJ, Ellis PA, Barnard MR, Michelson AD
Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost. 1994 Dec; 72(6):957-63.
Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood.
How platelets work: platelet function and dysfunction. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):7-12.
How platelets work: platelet function and dysfunction.
Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD
Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):645S-687S.
Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. Blood. 1987 Nov; 70(5):1673-8.
Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis. 1994 Feb; 5(1):121-31.
Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications.
Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD
Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001 Sep 18; 104(12):1374-9.
Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Platelet inhibitor therapy: mechanisms of action and clinical use. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):13-5.
Platelet inhibitor therapy: mechanisms of action and clinical use.
Krueger LA, Barnard MR, Frelinger AL, Furman MI, Michelson AD
Immunophenotypic analysis of platelets. Curr Protoc Cytom. 2002 Feb; Chapter 6:Unit 6.10.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19; 374(9694):989-997.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46.
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
The Journal of laboratory and clinical medicine
Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med. 1987 Sep; 110(3):346-54.
Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia.
Haemolytic anaemia associated with acquired toxoplasmosis. Aust Paediatr J. 1984 Nov; 20(4):333-5.
Haemolytic anaemia associated with acquired toxoplasmosis.
Current options in platelet function testing. Am J Cardiol. 2006 Nov 20; 98(10A):4N-10N.
Current options in platelet function testing.
Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD
Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 Dec 22; 120(25):2586-96.
Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Thrombophilia and pediatric stroke. Circulation. 2010 Apr 27; 121(16):1795-7.
Trenor CC, Chung RJ, Michelson AD, Neufeld EJ, Gordon CM, Laufer MR, Emans SJ
Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011 Feb; 127(2):347-57.
Hormonal contraception and thrombotic risk: a multidisciplinary approach.
Yamamoto N, Greco NJ, Barnard MR, Tanoue K, Yamazaki H, Jamieson GA, Michelson AD
Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. Blood. 1991 Apr 15; 77(8):1740-8.
Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation.
Loscalzo J, Freedman J, Inbal A, Keaney JF, Michelson AD, Vita JA
Transactions of the American Clinical and Climatological Association
Nitric oxide insufficiency and arterial thrombosis. Trans Am Clin Climatol Assoc. 2000; 111:158-63.
Nitric oxide insufficiency and arterial thrombosis.
Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000 Sep; 84(3):492-8.
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Michelson AD, Benoit SE, Furman MI, Barnard MR, Nurden P, Nurden AT
The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system. Blood. 1996 Feb 15; 87(4):1396-408.
The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system.
Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. Sci Rep. 2018 07 09; 8(1):10300.
Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia.
Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD
Journal of thrombosis and haemostasis : JTH
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011 Nov; 9(11):2302-10.
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.
Valeri CR, Macgregor H, Barnard MR, Summaria L, Michelson AD, Ragno G
In vitro testing of fresh and lyophilized reconstituted human and baboon platelets. Transfusion. 2004 Oct; 44(10):1505-12.
In vitro testing of fresh and lyophilized reconstituted human and baboon platelets.
Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Coller BS, Furie B, Hulot JS, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AA
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation. 2012 Sep 25; 126(13):1645-62.
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.
Serebruany VL, Oshrine BR, Malinin AI, Atar D, Michelson AD, Ferguson JJ
Noncompliance in cardiovascular clinical trials. Am Heart J. 2005 Nov; 150(5):882-6.
Noncompliance in cardiovascular clinical trials.
Michelson AD, Gore JM, Rybak ME, Cola CA, Barnard MR
Effect of in vivo infusion of recombinant tissue-type plasminogen activator on platelet glycoprotein Ib. Thromb Res. 1990 Dec 01; 60(5):421-4.
Effect of in vivo infusion of recombinant tissue-type plasminogen activator on platelet glycoprotein Ib.
The American journal of pediatric hematology/oncology
Chemotherapy-induced painful acral erythema in childhood: Burgdorf's reaction. Am J Pediatr Hematol Oncol. 1989; 11(1):44-5.
Chemotherapy-induced painful acral erythema in childhood: Burgdorf's reaction.
Frelinger AL, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26.
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Linden MD, Whittaker P, Frelinger AL, Barnard MR, Michelson AD, Przyklenk K
Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost. 2006 Dec; 4(12):2670-7.
Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation.
Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 02; 6(2):359-65.
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S
Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1.
Antiplatelet therapy and platelet function testing. Introduction.
Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD
Journal of the American College of Cardiology
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 03; 59(14):1304-11.
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Gremmel T, Michelson AD, Frelinger AL, Bhatt DL
Research and practice in thrombosis and haemostasis
Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018 Jul; 2(3):439-449.
Novel aspects of antiplatelet therapy in cardiovascular disease.
LaRosa CA, Rohrer MJ, Benoit SE, Barnard MR, Michelson AD
Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex. Blood. 1994 Jul 01; 84(1):158-68.
Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex.
Antithrombotic therapy in children. Chest. 1995 Oct; 108(4 Suppl):506S-522S.
Images in clinical medicine. A morphologic question. N Engl J Med. 1995 Oct 19; 333(16):1051.
Images in clinical medicine. A morphologic question.
Michelson AD, Wencel-Drake JD, Kestin AS, Barnard MR
Arteriosclerosis and thrombosis : a journal of vascular biology
Platelet activation results in a redistribution of glycoprotein IV (CD36). Arterioscler Thromb. 1994 Jul; 14(7):1193-201.
Platelet activation results in a redistribution of glycoprotein IV (CD36).
Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010 Feb; 9(2):154-69.
Antiplatelet therapies for the treatment of cardiovascular disease.
Adelman B, Michelson AD, Greenberg J, Handin RI
Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood. 1986 Dec; 68(6):1280-4.
Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions.
Frelinger AL, Barnard MR, Fox ML, Michelson AD
Circulation. Cardiovascular interventions
The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct; 3(5):442-9.
The Platelet Activity After Clopidogrel Termination (PACT) study.
Rahangdale S, Yeh SY, Novack V, Stevenson K, Barnard MR, Furman MI, Frelinger AL, Michelson AD, Malhotra A
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011 Apr 15; 7(2):172-8.
The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea.
Adelman B, Michelson AD, Handin RI, Ault KA
Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood. 1985 Aug; 66(2):423-7.
Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry.
Progress in clinical and biological research
Thrombin-induced changes in platelet membrane glycoproteins. Prog Clin Biol Res. 1988; 283:159-62.
Thrombin-induced changes in platelet membrane glycoproteins.
Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL
GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529.
GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation.
Michelson AD, Smolensky Koganov E, Forde EE, Carmichael SL, Frelinger AL
Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018 12; 16(12):2515-2519.
Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Frelinger AL, Gerrits AJ, Neculaes VB, Gremmel T, Torres AS, Caiafa A, Carmichael SL, Michelson AD
Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS One. 2018; 13(9):e0203557.
Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology.
Grabowski EF, Jang IK, Gold H, Palacios IF, Boor SE, Rodino LJ, Michelson AD
Platelet degranulation induced by some contrast media is independent of their nonionic vs ionic nature. Acta Radiol Suppl. 1995; 399:182-4.
Platelet degranulation induced by some contrast media is independent of their nonionic vs ionic nature.
Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646-7.
Clopidogrel linking evaluation of platelet response variability to mechanism of action.
American journal of respiratory and critical care medicine
The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med. 2006 Mar 01; 173(5):483-90.
The inflammatory role of platelets in cystic fibrosis.
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32.
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D, Clemetson KJ, Goodall AH, Michelson AD, Nurden AT, Shankey TV
European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998 May; 79(5):885-96.
European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function.
Himmelfarb J, Nelson S, McMonagle E, Holbrook D, Benoit SE, Michelson AD, Ault K
American journal of kidney diseases : the official journal of the National Kidney Foundation
Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. Am J Kidney Dis. 1998 Jul; 32(1):132-8.
Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients.
LaRosa CA, Rohrer MJ, Benoit SE, Rodino LJ, Barnard MR, Michelson AD
Human neutrophil cathepsin G is a potent platelet activator. J Vasc Surg. 1994 Feb; 19(2):306-18; discussion 318-9.
Human neutrophil cathepsin G is a potent platelet activator.
Li JM, Podolsky RS, Rohrer MJ, Cutler BS, Massie MT, Barnard MR, Michelson AD
Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. J Surg Res. 1996 Mar; 61(2):543-8.
Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa.
Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD
Effect of strenuous exercise on platelet activation state and reactivity. Circulation. 1993 Oct; 88(4 Pt 1):1502-11.
Effect of strenuous exercise on platelet activation state and reactivity.
Alugupalli KR, Michelson AD, Joris I, Schwan TG, Hodivala-Dilke K, Hynes RO, Leong JM
Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis. Blood. 2003 Oct 15; 102(8):2843-50.
Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis.
Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 Nov 29; 8(1):17580.
Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation.
Orchard MA, Goodchild CS, Prentice CR, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, Michelson AD
Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol. 1993 Nov; 85(3):533-41.
Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets.
Grabowski EF, Head C, Michail HA, Jang IK, Gold H, Benoit SE, Michelson AD
Effects of contrast media on platelet activation using flowing whole blood aggregometry and flow cytometry of platelet membrane glycoproteins. Invest Radiol. 1994 Jun; 29 Suppl 2:S198-200.
Effects of contrast media on platelet activation using flowing whole blood aggregometry and flow cytometry of platelet membrane glycoproteins.
Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD
Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 Dec; 6(12):2035-44.
Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests.
Grabowski EF, Boor SE, Rodino LJ, Jang IK, Gold H, Michelson AD
Platelets are degranulated by some, but not all, contrast media. Acad Radiol. 1996 Aug; 3 Suppl 2:S328-30.
Platelets are degranulated by some, but not all, contrast media.
Peyton BD, Rohrer MJ, Furman MI, Barnard MR, Rodino LJ, Benoit SE, Hechtman HB, Valeri CR, Michelson AD
Patients with venous stasis ulceration have increased monocyte-platelet aggregation. J Vasc Surg. 1998 Jun; 27(6):1109-15; discussion 1115-6.
Patients with venous stasis ulceration have increased monocyte-platelet aggregation.
Charnigo RJ, Beidler D, Rybin D, Pittman DD, Tan B, Howard J, Michelson AD, Frelinger AL, Clarke N
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. Clin Transl Sci. 2019 03; 12(2):180-188.
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study.
Alugupalli KR, Michelson AD, Barnard MR, Leong JM
Serial determinations of platelet counts in mice by flow cytometry. Thromb Haemost. 2001 Aug; 86(2):668-71.
Serial determinations of platelet counts in mice by flow cytometry.
Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 Jun; 87(6):1020-5.
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9.
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Flow cytometric assessment of glycoprotein movements in platelets. Platelets. 1997; 8(2-3):105-15.
Flow cytometric assessment of glycoprotein movements in platelets.
Garner AL, Frelinger AL, Gerrits AJ, Gremmel T, Forde EE, Carmichael SL, Michelson AD, Neculaes VB
Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Med Hypotheses. 2019 Apr; 125:100-105.
Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting.
May LJ, Liu X, Tesoro T, Yang J, Lo C, Chen S, Murray J, Rosenthal DN, Massicotte P, Michelson AD, Almond CS
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Usefulness of anti-platelet therapy testing in children supported with a ventricular assist device. J Heart Lung Transplant. 2019 07; 38(7):781-783.
Usefulness of anti-platelet therapy testing in children supported with a ventricular assist device.
Robert E. Gross Professor of Surgery, Emeritus
James and Thea Stoneman Associate Professor of Surgery in the Field of Vascular Biology
Pina LM, Dong X, Zhang L, Samtani MN, Michelson AD, Justino H, Bonnet D, Harris KC, Jefferies J, McCrindle BW, Li JS
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). Am Heart J. 2019 07; 213:97-104.
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study).
W. Hardy Hendren Professor of Surgery, Emeritus
John A. Kirkpatrick Professor of Radiology, Emeritus
John E. Hall Professor of Orthopedic Surgery, Emeritus
Corresponding Member of the Faculty of Pediatrics
Heeney MM, Abboud MR, Amilon C, Andersson M, Githanga J, Inusa B, Kanter J, Leonsson-Zachrisson M, Michelson AD, Berggren AR
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemp Clin Trials. 2019 10; 85:105835.
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3).
Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL, Michelson AD, Morrow L, Hall M, Currie MG, Milne GT, Profy AT
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020 04; 63(4):733-743.
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Zhou C, Zhuang Y, Lin X, Michelson AD, Zhang A
Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis. Br J Haematol. 2020 03; 188(6):945-961.
Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis.
Journal of cardiovascular pharmacology and therapeutics
Novel Antiplatelet Agents in Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2020 05; 25(3):191-200.
Novel Antiplatelet Agents in Cardiovascular Disease.
Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL, Cange AL, Sabatine MS, O'Donoghue ML
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681.
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.
Sims MC, Mayer L, Collins JH, Bariana TK, Megy K, Lavenu-Bombled C, Seyres D, Kollipara L, Burden FS, Greene D, Lee D, Rodriguez-Romera A, Alessi MC, Astle WJ, Bahou WF, Bury L, Chalmers E, Da Silva R, De Candia E, Deevi SVV, Farrow S, Gomez K, Grassi L, Greinacher A, Gresele P, Hart D, Hurtaud MF, Kelly AM, Kerr R, Le Quellec S, Leblanc T, Leinøe EB, Mapeta R, McKinney H, Michelson AD, Morais S, Nugent D, Papadia S, Park SJ, Pasi J, Podda GM, Poon MC, Reed R, Sekhar M, Shalev H, Sivapalaratnam S, Steinberg-Shemer O, Stephens JC, Tait RC, Turro E, Wu JKM, Zieger B, Kuijpers TW, Whetton AD, Sickmann A, Freson K, Downes K, Erber WN, Frontini M, Nurden P, Ouwehand WH, Favier R, Guerrero JA
Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood. 2020 10 22; 136(17):1956-1967.
Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome.
Ariens R, Becattini C, Bender M, Bergmeier W, Castoldi E, Devreese K, Ellis M, Gailani D, Ignjatovic V, James PD, Kerrigan S, Lambert M, Lee LH, Levi M, Maugeri N, Meijers J, Melero-Martin J, Michelson AD, Mingozzi F, Neeves K, Ni H, Olsson AK, Prohászka Z, Ranson M, Riva N, Senis Y, van Ommen CH, Vaughan DE, Weisel J
Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost. 2020 Jul; 4(5):680-713.
Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress.
Pittman DD, Hines PC, Beidler D, Rybin D, Frelinger AL, Michelson AD, Liu K, Gao X, White J, Zaidi AU, Charnigo RJ, Callaghan MU
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. Blood. 2021 04 15; 137(15):2010-2020.
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers.
Mazzeffi M, Tanaka K, Wu YF, Zhang A, Kareddy N, Tadjou Tito E, Rock P, Michelson AD, Frelinger AL
Platelet surface GPIba, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients. Platelets. 2022 Jan 02; 33(1):116-122.
Platelet surface GPIba, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients.
Croteau SE, Frelinger AL, Gerrits AJ, Michelson AD
Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982.
Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency.
Spurgeon BEJ, Michelson AD, Frelinger AL
Cytometry. Part A : the journal of the International Society for Analytical Cytology
Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters. Cytometry A. 2021 02; 99(2):170-179.
Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters.
Wahlster L, Verboon JM, Ludwig LS, Black SC, Luo W, Garg K, Voit RA, Collins RL, Garimella K, Costello M, Chao KR, Goodrich JK, DiTroia SP, O'Donnell-Luria A, Talkowski ME, Michelson AD, Cantor AB, Sankaran VG
Familial thrombocytopenia due to a complex structural variant resulting in a WAC-ANKRD26 fusion transcript. J Exp Med. 2021 06 07; 218(6).
Familial thrombocytopenia due to a complex structural variant resulting in a WAC-ANKRD26 fusion transcript.
Neculaes B, Frelinger AL, Gerrits AJ, Gremmel T, Forde EE, Klopman S, Carmichael SL, Michelson AD
Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. PLoS One. 2021; 16(4):e0249209.
Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin.
Platelet Immunophenotyping by High-Dimensional Mass Cytometry. Curr Protoc. 2021 May; 1(5):e112.
Platelet Immunophenotyping by High-Dimensional Mass Cytometry.
Spurgeon BEJ, Linden MD, Michelson AD, Frelinger AL
Immunophenotypic Analysis of Platelets by Flow Cytometry. Curr Protoc. 2021 Jun; 1(6):e178.
Immunophenotypic Analysis of Platelets by Flow Cytometry.
Zhu P, Willmann S, Zhou W, Yang H, Michelson AD, McCrindle BW, Li JS, Harris KC, Pina LM, Weber T, Nessel K, Lesko LJ, Kubitza D, Zannikos P
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. J Clin Pharmacol. 2022 02; 62(2):220-231.
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.
Revel-Vilk S, Naamad M, Frydman D, Freund MR, Dinur T, Istaiti M, Becker-Cohen M, Falk R, Broide E, Michelson AD, Frelinger AL, Zimran A
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease. Thromb Haemost. 2022 06; 122(6):951-960.
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease.
McCrindle BW, Michelson AD, Van Bergen AH, Suzana Horowitz E, Pablo Sandoval J, Justino H, Harris KC, Jefferies JL, Miriam Pina L, Peluso C, Nessel K, Lu W, Li JS
Journal of the American Heart Association
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. J Am Heart Assoc. 2021 11 16; 10(22):e021765.
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.
Frelinger AL, Rivera J, Connor DE, Freson K, Greinacher A, Harrison P, Kunishima S, Lordkipanidzé M, Michelson AD, Ramström S, Gresele P
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2021 12; 19(12):3193-3202.
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology.
Gremmel T, Michelson AD, Wadowski PP, Pultar J, Weikert C, Tscharre M, Lee S, Panzer S, Frelinger AL
Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis. 2021 12; 339:12-19.
Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization.
Hardin J, Michelson AD, McCrindle BW, Pina LM, Peluso C, Simpkins P, Truong H, Knoll C, Yuan Z
Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children. Clin Ther. 2021 12; 43(12):2074-2087.
Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children.
Poli V, Di Gioia M, Sola-Visner M, Granucci F, Frelinger AL, Michelson AD, Zanoni I
Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia. Immunity. 2022 02 08; 55(2):224-236.e5.
Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia.
Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Åstrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 2022 09 29; 140(13):1470-1481.
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Frelinger AL, Haynes RL, Goldstein RD, Berny-Lang MA, Gerrits AJ, Riehs M, Haas EA, Paunovic B, Mena OJ, Campman SC, Milne GL, Sleeper LA, Kinney HC, Michelson AD
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 05 15; 14(1):11092.
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome.
Platelet Physiology. Semin Thromb Hemost. 2024 Nov; 50(8):1173-1186.
Michelson AD, Frelinger Iii AL, Haynes RL, Kinney HC, Gremmel T
Platelet Pathophysiology: Unexpected New Research Directions. Semin Thromb Hemost. 2024 Nov; 50(8):1187-1190.
Platelet Pathophysiology: Unexpected New Research Directions.
Hosemann W, Michelson A, Weindler J, Mang H, Wigand ME
[The effect of endonasal paranasal sinus surgery on lung function of patients with bronchial asthma]. Laryngorhinootologie. 1990 Oct; 69(10):521-6.
[The effect of endonasal paranasal sinus surgery on lung function of patients with bronchial asthma].
Michelson A, Schuster B, Thias S, Haid CT
[Vestibular lesion in sudden deafness: a prognostic criterium for therapeutic success]. Laryngorhinootologie. 1995 Jan; 74(1):7-12.
[Vestibular lesion in sudden deafness: a prognostic criterium for therapeutic success].
Psaila B, Bussel JB, Frelinger AL, Michelson AD
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. J Thromb Haemost. 2013 May; 11(5):1002-3.
Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal.
Hematology. American Society of Hematology. Education Program
Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011; 2011:62-9.
Jennings LK, Michelson AD, Jacoski MV, Tyagi A, Grgurevich S, Li JS
Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. Platelets. 2012; 23(6):430-8.
Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response.
Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL
P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 May 15; 2(3):e000026.
P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Gray platelet syndrome. Blood. 2013 Jan 10; 121(2):250.
Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DH, Steinberg MH, Frelinger AL, Michelson AD, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ
The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85.
The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation.
Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7.
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Wahlster L, Godley LA, Cheng JX, Drazer MW, Reilly CR, Pinkus GS, Rowe JH, Weichert-Leahey N, Rowe RG, Gorfinkel L, Brundige K, Wachter F, Messa L, Michelson AD, Cantor AB, Shimamura A, Bledsoe JR
ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance. Blood. 2025 Jul 10; 146(2):254-259.
ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance.
Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G
Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 2014 Jan; 12(1):2-13.
Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.
Darling CE, Sala Mercado JA, Quiroga-Castro W, Tecco GF, Zelaya FR, Conci EC, Sala JP, Smith CS, Michelson AD, Whittaker P, Welch RD, Przyklenk K
Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. BMJ Open. 2014 Jan 17; 4(1):e003883.
Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study.
Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD
Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35.
Platelet activation and inhibition in sickle cell disease (pains) study.
Chang H, Yanachkov IB, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, Michelson AD, Frelinger AL
Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780.
Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate.
Panin N, Torres L, Patel Y, Michelson A, Hung A, El-Hashash AH
Innovative approaches in neural stem cell therapy: a comprehensive review of mechanisms and applications. Am J Stem Cells. 2025; 14(4):230-243.
Innovative approaches in neural stem cell therapy: a comprehensive review of mechanisms and applications.
Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, O'Donoghue ML, Sabatine MS, Mega JL
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8.
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.
Torres AS, Caiafa A, Garner AL, Klopman S, LaPlante N, Morton C, Conway K, Michelson AD, Frelinger AL, Neculaes VB
The journal of trauma and acute care surgery
Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. J Trauma Acute Care Surg. 2014 Sep; 77(3 Suppl 2):S94-S100.
Platelet activation using electric pulse stimulation: growth factor profile and clinical implications.
McCrindle BW, Li JS, Manlhiot C, Tweddell JS, Giglia TM, Massicotte MP, Monagle P, Krishnamurthy R, Mahaffey KW, Michelson AD, Verdun N, Almond CS, Newburger JW, Brandão LR, Esmon CT, Manco-Johnson MJ, Ichord R, Ortel TL, Chan AK, Portman R, Rose M, Strony J, Kaltman JR
Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. Circulation. 2014 Sep 30; 130(14):1192-203.
Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease.
Berny-Lang MA, Darling CE, Frelinger AL, Barnard MR, Smith CS, Michelson AD
International journal of laboratory hematology
Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? Int J Lab Hematol. 2015 Feb; 37(1):112-9.
Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?
Sakurai Y, Fitch-Tewfik JL, Qiu Y, Ahn B, Myers DR, Tran R, Fay ME, Ding L, Spearman PW, Michelson AD, Flaumenhaft R, Lam WA
Platelet geometry sensing spatially regulates a-granule secretion to enable matrix self-deposition. Blood. 2015 Jul 23; 126(4):531-8.
Platelet geometry sensing spatially regulates a-granule secretion to enable matrix self-deposition.
Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS One. 2015; 10(8):e0134599.
Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization.
Frelinger AL, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD
Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9.
Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP.
Gerrits AJ, Leven EA, Frelinger AL, Brigstocke SL, Berny-Lang MA, Mitchell WB, Revel-Vilk S, Tamary H, Carmichael SL, Barnard MR, Michelson AD, Bussel JB
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10; 126(11):1367-78.
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia.
Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18.
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, Michelson AD, Frelinger AL, Przyklenk K
Arteriosclerosis, thrombosis, and vascular biology
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9.
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Frelinger AL, Torres AS, Caiafa A, Morton CA, Berny-Lang MA, Gerrits AJ, Carmichael SL, Neculaes VB, Michelson AD
Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation. Platelets. 2016; 27(2):128-35.
Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation.
Platelet Physiology. Semin Thromb Hemost. 2016 Apr; 42(3):191-204.
Brun C, Daali Y, Combescure C, Zufferey A, Michelson AD, Fontana P, Reny JL, Frelinger AL
Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016; 27(3):196-202.
Aspirin response: Differences in serum thromboxane B2 levels between clinical studies.
In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16.
In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization.
Carreras ET, Hochholzer W, Frelinger AL, Nordio F, O'Donoghue ML, Wiviott SD, Angiolillo DJ, Michelson AD, Sabatine MS, Mega JL
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 07 04; 116(1):69-77.
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Jain A, van der Meer AD, Papa AL, Barrile R, Lai A, Schlechter BL, Otieno MA, Louden CS, Hamilton GA, Michelson AD, Frelinger AL, Ingber DE
Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed Microdevices. 2016 08; 18(4):73.
Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium.
Frelinger AL, Gerrits AJ, Garner AL, Torres AS, Caiafa A, Morton CA, Berny-Lang MA, Carmichael SL, Neculaes VB, Michelson AD
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma. PLoS One. 2016; 11(8):e0160933.
Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma.
Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. Hematology Am Soc Hematol Educ Program. 2000; 222-240.
Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease.
Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, Lussana F, Pugliano MT, Michelson AD
Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost. 2013 Apr 10.
Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH.
Whole Blood Analysis of Leukocyte-Platelet Aggregates. Curr Protoc Cytom. 2016 10 10; 78:6.15.1-6.15.10.
Whole Blood Analysis of Leukocyte-Platelet Aggregates.
Upchurch GR, Valeri CR, Khuri SF, Rohrer MJ, Welch GN, MacGregor H, Ragno G, Francis S, Rodino LJ, Michelson AD, Loscalzo J
Effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol. 1996 Aug; 271(2 Pt 2):H528-34.
Effect of heparin on fibrinolytic activity and platelet function in vivo.
Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR
Proceedings of the National Academy of Sciences of the United States of America
In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11877-82.
In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.
Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J
Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol. 1996 May; 270(5 Pt 2):H1640-8.
Effects of nitric oxide/EDRF on platelet surface glycoproteins.
Pathophysiology of haemostasis and thrombosis
Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb. 2006; 35(1-2):67-82.
Evaluation of platelet function by flow cytometry.
Grabowski EF, Jang IK, Gold H, Head C, Benoit SE, Michelson AD
Variability of platelet degranulation by different contrast media. Acad Radiol. 1996 Sep; 3 Suppl 3:S485-7.
Variability of platelet degranulation by different contrast media.
Gerrits AJ, Jakubowski JA, Sugidachi A, Michelson AD, Frelinger AL
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost. 2017 05; 15(5):858-867.
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998 Feb; 31(2):352-8.
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.
Eikelboom J, Feldman M, Mehta SR, Michelson AD, Oates JA, Topol E
Aspirin resistance and its implications in clinical practice. MedGenMed. 2005 Jul 11; 7(3):76.
Aspirin resistance and its implications in clinical practice.
Aspirin resistance. Pathophysiol Haemost Thromb. 2006; 35(1-2):5-9.
Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007 Jan; 5(1):75-81.
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Platelet function in the newborn. Semin Thromb Hemost. 1998; 24(6):507-12.
Barnard MR, MacGregor H, Mercier R, Ragno G, Pivacek LE, Hechtman HB, Michelson AD, Valeri CR
Platelet surface p-selectin, platelet-granulocyte heterotypic aggregates, and plasma-soluble p-selectin during plateletpheresis. Transfusion. 1999 Jul; 39(7):735-41.
Platelet surface p-selectin, platelet-granulocyte heterotypic aggregates, and plasma-soluble p-selectin during plateletpheresis.
Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, Vavva F, Brand N, Michelson A, Trolliet M, Loscalzo J, Inbal A
Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol. 1999 Aug; 19(8):2017-23.
Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke.
Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999 Sep; 6(5):342-8.
Laboratory markers of platelet activation and their clinical significance.
Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6.
Assessing the current role of platelet function testing.
Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65.
Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors.
Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, Michelson AD
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003 Nov 01; 92(9):1099-101.
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
Alugupalli KR, Michelson AD, Barnard MR, Robbins D, Coburn J, Baker EK, Ginsberg MH, Schwan TG, Leong JM
Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIbbeta3 activation. Mol Microbiol. 2001 Jan; 39(2):330-40.
Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIbbeta3 activation.
Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL, Goldberg RJ, Michelson AD
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001 Oct; 38(4):1002-6.
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.
Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J. 2003 Feb; 145(2):e6.
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK
Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005 Jun; 3(6):1309-11.
Aspirin resistance: position paper of the Working Group on Aspirin Resistance.
Wiviott SD, Michelson AD, Berger PB, Lepor NE, Kereiakes DJ
Therapeutic goals for effective platelet inhibition: a consensus document. Rev Cardiovasc Med. 2006; 7(4):214-25.
Therapeutic goals for effective platelet inhibition: a consensus document.
Michelson AD, Barnard MR, Krueger LA, Frelinger AL, Furman MI
Evaluation of platelet function by flow cytometry. Methods. 2000 Jul; 21(3):259-70.
Scheer FA, Michelson AD, Frelinger AL, Evoniuk H, Kelly EE, McCarthy M, Doamekpor LA, Barnard MR, Shea SA
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011; 6(9):e24549.
The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors.
Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9.
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Michelson AD, Ellis PA, Barnard MR, Matic GB, Viles AF, Kestin AS
Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood. 1991 Feb 15; 77(4):770-9.
Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound.
Linden MD, Furman MI, Frelinger AL, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD
Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007 Apr; 5(4):761-5.
Indices of platelet activation and the stability of coronary artery disease.
Furman MI, Liu L, Benoit SE, Becker RC, Barnard MR, Michelson AD
The cleaved peptide of the thrombin receptor is a strong platelet agonist. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3082-7.
The cleaved peptide of the thrombin receptor is a strong platelet agonist.
Barnard MR, MacGregor H, Ragno G, Pivacek LE, Khuri SF, Michelson AD, Valeri CR
Fresh, liquid-preserved, and cryopreserved platelets: adhesive surface receptors and membrane procoagulant activity. Transfusion. 1999 Aug; 39(8):880-8.
Fresh, liquid-preserved, and cryopreserved platelets: adhesive surface receptors and membrane procoagulant activity.
Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, Michelson AD
Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004 Jun 16; 43(12):2319-25.
Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Michelson AD, Barnard MR, Khuri SF, Rohrer MJ, MacGregor H, Valeri CR
The effects of aspirin and hypothermia on platelet function in vivo. Br J Haematol. 1999 Jan; 104(1):64-8.
The effects of aspirin and hypothermia on platelet function in vivo.
Pigazzi A, Heydrick S, Folli F, Benoit S, Michelson A, Loscalzo J
Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem. 1999 May 14; 274(20):14368-75.
Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets.
Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI
Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001 Sep 25; 104(13):1533-7.
Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction.
Plasmin-induced redistribution of platelet glycoprotein Ib. Blood. 1990 Nov 15; 76(10):2005-10.
Plasmin-induced redistribution of platelet glycoprotein Ib.
Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-IX complex. Semin Thromb Hemost. 1992 Jan; 18(1):18-27.
Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-IX complex.
Harrison P, Frelinger AL, Furman MI, Michelson AD
Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007; 120(3):323-36.
Measuring antiplatelet drug effects in the laboratory.
Claytor RB, Michelson AD, Li JM, Frelinger AL, Rohrer MJ, Garnette CS, Barnard MR, Krueger LA, Furman MI
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg. 2003 Feb; 37(2):440-5.
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin.
Gardiner EE, De Luca M, McNally T, Michelson AD, Andrews RK, Berndt MC
Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. Blood. 2001 Sep 01; 98(5):1440-7.
Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G.
Matic GB, Jaspers SR, Miller TB, Michelson AD
Platelet glycogen synthase: further characterization and effect of insulin. Thromb Res. 1991 Aug 15; 63(4):427-32.
Platelet glycogen synthase: further characterization and effect of insulin.
Thrombocytopenia associated with environmental exposure to polyurethane. Am J Hematol. 1991 Oct; 38(2):145-6.
Thrombocytopenia associated with environmental exposure to polyurethane.
Michelson AD, Bovill E, Monagle P, Andrew M
Antithrombotic therapy in children. Chest. 1998 Nov; 114(5 Suppl):748S-769S.
How I use laboratory monitoring of antiplatelet therapy. Blood. 2017 08 10; 130(6):713-721.
How I use laboratory monitoring of antiplatelet therapy.
Bednarek FJ, Bean S, Barnard MR, Frelinger AL, Michelson AD
The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thromb Res. 2009 May; 124(1):42-5.
The platelet hyporeactivity of extremely low birth weight neonates is age-dependent.
Frelinger AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 Jun 27; 113(25):2888-96.
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Neonatal platelet function. Semin Thromb Hemost. 2003 Aug; 29(4):363-72.
Arterial ischemic stroke in children: baby steps. Circulation. 2006 Nov 14; 114(20):2094-5.
Arterial ischemic stroke in children: baby steps.
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35.
Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36.
Antiplatelet therapy and platelet function testing.
Rohrer MJ, Kestin AS, Ellis PA, Barnard MR, Rodino L, Breckwoldt WL, Li JM, Michelson AD
High-dose heparin suppresses platelet alpha granule secretion. J Vasc Surg. 1992 Jun; 15(6):1000-8; discussion 1008-9.
High-dose heparin suppresses platelet alpha granule secretion.
Michelson AD, Rajasekhar D, Bednarek FJ, Barnard MR
Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. Thromb Haemost. 2000 Oct; 84(4):689-94.
Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults.
Rohrer MJ, Claytor RB, Garnette CS, Powell CC, Barnard MR, Furman MI, Michelson AD
Cardiovascular surgery (London, England)
Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux. Cardiovasc Surg. 2002 Oct; 10(5):464-9.
Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux.
Chen J, Dong JF, Sun C, Bergeron A, McBride L, Pillai M, Barnard MR, Salmon J, Michelson AD, Bray PF
Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. J Thromb Haemost. 2003 Feb; 1(2):355-62.
Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation.
Transient neurological disorder associated with transient erythroblastopenia of childhood. Am J Pediatr Hematol Oncol. 1987; 9(2):161-3.
Transient neurological disorder associated with transient erythroblastopenia of childhood.
Haynes RL, Frelinger AL, Giles EK, Goldstein RD, Tran H, Kozakewich HP, Haas EA, Gerrits AJ, Mena OJ, Trachtenberg FL, Paterson DS, Berry GT, Adeli K, Kinney HC, Michelson AD
High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci U S A. 2017 07 18; 114(29):7695-7700.
High serum serotonin in sudden infant death syndrome.
Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD
Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996 Feb 15; 97(4):979-87.
Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis.
O'Sullivan BP, Linden MD, Frelinger AL, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD
Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41.
Valeri CR, MacGregor H, Barnard MR, Summaria L, Michelson AD, Ragno G
Survival of baboon biotin-X-N-hydroxysuccinimide and (111)In-oxine-labelled autologous fresh and lyophilized reconstituted platelets. Vox Sang. 2005 Feb; 88(2):122-9.
Survival of baboon biotin-X-N-hydroxysuccinimide and (111)In-oxine-labelled autologous fresh and lyophilized reconstituted platelets.
Barnard MR, Linden MD, Frelinger AL, Li Y, Fox ML, Furman MI, Michelson AD
Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005 Nov; 3(11):2563-70.
Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity.
Darling CE, Michelson AD, Volturo GA, Przyklenk K
Platelet reactivity and the identification of acute coronary syndromes in the emergency department. J Thromb Thrombolysis. 2009 Jul; 28(1):31-7.
Platelet reactivity and the identification of acute coronary syndromes in the emergency department.
Barnard MR, Krueger LA, Frelinger AL, Furman MI, Michelson AD
Whole blood analysis of leukocyte-platelet aggregates. Curr Protoc Cytom. 2003 May; Chapter 6:Unit 6.15.
Whole blood analysis of leukocyte-platelet aggregates.
Trier DA, Gank KD, Kupferwasser D, Yount NY, French WJ, Michelson AD, Kupferwasser LI, Xiong YQ, Bayer AS, Yeaman MR
Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect Immun. 2008 Dec; 76(12):5706-13.
Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release.
Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, Birjiniuk V, Michelson AD, Gagnon DR, Valeri CR
The Journal of thoracic and cardiovascular surgery
Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999 Jan; 117(1):172-83; discussion 183-4.
Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass.
Powell CC, Rohrer MJ, Barnard MR, Peyton BD, Furman MI, Michelson AD
Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg. 1999 Nov; 30(5):844-51.
Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation.
Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000 Mar 07; 101(9):1013-8.
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
Furman MI, Nurden P, Berndt MC, Nurden AT, Benoit SE, Barnard MR, Ofosu FA, Michelson AD
The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb Haemost. 2000 Nov; 84(5):897-903.
The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system.
Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD
Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007 Nov 06; 50(19):1822-34.
Platelet function monitoring in patients with coronary artery disease.
Methods for the measurement of platelet function. Am J Cardiol. 2009 Feb 02; 103(3 Suppl):20A-26A.
Methods for the measurement of platelet function.
Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD
Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009 Jun; 7(6):1029.
Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH.
Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8.
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
New P2Y12 antagonists. Curr Opin Hematol. 2009 Sep; 16(5):371-7.
Nonionic contrast media. Procoagulants or clotting innocents? Invest Radiol. 1993 Nov; 28 Suppl 5:S21-4.
Nonionic contrast media. Procoagulants or clotting innocents?
Flow cytometry: a clinical test of platelet function. Blood. 1996 Jun 15; 87(12):4925-36.
Flow cytometry: a clinical test of platelet function.
Linden MD, Frelinger AL, Barnard MR, Przyklenk K, Furman MI, Michelson AD
Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004 Oct; 30(5):501-11.
Application of flow cytometry to platelet disorders.
Platelet activation and progression to complications. Rev Cardiovasc Med. 2006; 7(2):75-81.
Platelet activation and progression to complications.
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20.
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.
Ferrer-Marin F, Chavda C, Lampa M, Michelson AD, Frelinger AL, Sola-Visner M
Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost. 2011 May; 9(5):1020-8.
Effects of in vitro adult platelet transfusions on neonatal hemostasis.
Granule exocytosis is required for platelet spreading: differential sorting of a-granules expressing VAMP-7. Blood. 2012 Jul 05; 120(1):199-206.
Granule exocytosis is required for platelet spreading: differential sorting of a-granules expressing VAMP-7.
Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI
Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985 Jan; 65(1):32-40.
Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions.
Michelson AD, Adelman B, Barnard MR, Carroll E, Handin RI
Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib. J Clin Invest. 1988 Jun; 81(6):1734-40.
Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib.
Flow cytometric analysis of platelets. Vox Sang. 2000; 78 Suppl 2:137-42.
Furman MI, Frelinger III AL, Michelson AD
Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents. Curr Cardiol Rep. 2000 Sep; 2(5):386-94.
Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.
Claytor RB, Li JM, Furman MI, Garnette CS, Rohrer MJ, Barnard MR, Krueger LA, Frelinger AL, Michelson AD
Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion. Cytometry. 2001 Apr 01; 43(4):308-13.
Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion.
Mitchell WB, Li JH, Singh F, Michelson AD, Bussel J, Coller BS, French DL
Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis. Blood. 2003 Mar 15; 101(6):2268-76.
Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis.
Linden MD, Barnard MR, Frelinger AL, Michelson AD, Przyklenk K
Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res. 2008; 121(5):689-98.
Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models.
Immature platelet fraction in immune thrombocytopenia: Useful in diagnosis but does it predict bleeding? Pediatr Blood Cancer. 2018 02; 65(2).
Immature platelet fraction in immune thrombocytopenia: Useful in diagnosis but does it predict bleeding?
Furman MI, Krueger LA, Linden MD, Fox ML, Ball SP, Barnard MR, Frelinger AL, Michelson AD
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 2005 Feb; 3(2):312-20.
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
GPIIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis. 2004 Aug; 18(1):11-7.
GPIIb/IIIa inhibitor-induced dethrombosis.
Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, Michelson AD
Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):887S-968S.
Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Flow cytometric detection of distinct subpopulations of platelets in individual patients. Prog Clin Biol Res. 1988; 283:131-6.
Flow cytometric detection of distinct subpopulations of platelets in individual patients.
Andrew M, Michelson AD, Bovill T, Leaker M, Massicotte P, Marzinotto V, Brooker LA
Journal of pediatric hematology/oncology
The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):7-22.
The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs.
Platelet function testing in cardiovascular diseases. Circulation. 2004 Nov 09; 110(19):e489-93.
Platelet function testing in cardiovascular diseases.
Antiplatelet therapy in children. Thromb Res. 2006; 118(1):75-83.
Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, Domanski M
Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006 Sep 01; 98(5):577-9.
Frequency of aspirin resistance in a community hospital.
Monagle P, Michelson AD, Bovill E, Andrew M
Antithrombotic therapy in children. Chest. 2001 Jan; 119(1 Suppl):344S-370S.
Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, Michelson AD
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation. 2008 Jan 29; 117(4):553-9.
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.
Tarnow I, Kristensen AT, Krogh AK, Frelinger AL, Barnard MR, Michelson AD
Veterinary immunology and immunopathology
Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):345-52.
Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation.
Tarnow I, Michelson AD, Barnard MR, Frelinger AL, Aasted B, Jensen BR, Parving HH, Rossing P, Tarnow L
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009 Nov; 20(7):513-9.
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.
Lajer M, Tarnow I, Michelson AD, Jorsal A, Frelinger AL, Parving HH, Rossing P, Tarnow L
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21(7):525-32.
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
Michelson AD, Benoit SE, Kroll MH, Li JM, Rohrer MJ, Kestin AS, Barnard MR
The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood. 1994 Jun 15; 83(12):3562-73.
The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible.
Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7.
Investigating the mechanisms of hyporesponse to antiplatelet approaches.
Michelson AD, Loscalzo J, Melnick B, Coller BS, Handin RI
Partial characterization of a binding site for von Willebrand factor on glycocalicin. Blood. 1986 Jan; 67(1):19-26.
Partial characterization of a binding site for von Willebrand factor on glycocalicin.
Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR
Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 1994 May; 71(5):633-40.
Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro.
Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200.
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):s33-8.
P2Y12 antagonism: promises and challenges.
Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, Michelson AD
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72.
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Frelinger AL, Grace RF, Gerrits AJ, Carmichael SL, Forde EE, Michelson AD
Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thromb Haemost. 2018 01; 118(1):143-151.
Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity.
Kamat SG, Michelson AD, Benoit SE, Moake JL, Rajasekhar D, Hellums JD, Kroll MH, Schafer AI
Fibrinolysis inhibits shear stress-induced platelet aggregation. Circulation. 1995 Sep 15; 92(6):1399-407.
Fibrinolysis inhibits shear stress-induced platelet aggregation.
Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63.
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Przyklenk K, Frelinger AL, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma H, Michelson AD
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010 Feb; 8(2):331-40.
Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.
Gerrits AJ, Jakubowski JA, Michelson AD, Frelinger AL
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. J Thromb Haemost. 2018 03; 16(3):607-608.
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply.
Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li JM, Valeri CR, Michelson AD
Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg. 1996 Oct; 112(4):1098-107.
Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid.
Chang H, Yanachkov IB, Dix EJ, Li YF, Barnard MR, Wright GE, Michelson AD, Frelinger AL
Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec; 10(12):2573-80.
Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation.
Tarnow I, Michelson AD, Frelinger AL, Linden MD, Li Y, Fox ML, Barnard MR, O'Sullivan BP
Cystic fibrosis heterozygotes do not have increased platelet activation. Thromb Res. 2007; 121(2):159-62.
Cystic fibrosis heterozygotes do not have increased platelet activation.
Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J. 2002 Apr; 143(4):602-11.
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
Platelet function testing in cardiovascular diseases. Hematology. 2005; 10 Suppl 1:132-7.
Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP
Guidelines for antithrombotic therapy in pediatric patients. J Pediatr. 1998 Apr; 132(4):575-88.
Guidelines for antithrombotic therapy in pediatric patients.
Inheritance of Diamond-Blackfan anemia. Med J Aust. 1982 Oct 30; 2(9):409-10.
Rajasekhar D, Barnard MR, Bednarek FJ, Michelson AD
Platelet hyporeactivity in very low birth weight neonates. Thromb Haemost. 1997 May; 77(5):1002-7.
Platelet hyporeactivity in very low birth weight neonates.
Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD
Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997 Jul 15; 100(2):350-6.
Nitric oxide released from activated platelets inhibits platelet recruitment.